Skip to main content
. 2021 Sep;9(9):3431–3439.e4. doi: 10.1016/j.jaip.2021.04.055

Table III.

Overall adjusted cause-specific hazard ratios (HRs) for switching to an angiotensin-II receptor blocker after angiotensin converting enzyme inhibitor therapy, stratified by British Thoracic Society asthma treatment step

British Thoracic Society asthma treatment step With asthma, n (%) Crude HR (95% CI) Crude P Adjusted HR (95% CI) Adjusted P
Age ≥60 y
 ≥3 9057 (45.6) 1.47 (1.44-1.51) <.001 1.35 (1.32-1.39) <.001
 2 5774 (29.1) 1.22 (1.18-1.26) <.001 1.13 (1.09-1.17) <.001
 1 5026 (25.3) 1.23 (1.19-1.28) <.001 1.14 (1.09-1.19) <.001
Age <60 y
 ≥3 9398 (44.6) 1.27 (1.23-1.30) <.001 1.18 (1.15-1.22) <.001
 2 4982 (23.6) 1.09 (1.05-1.14) <.001 1.02 (0.96-1.07) .753
 1 6716 (31.8) 0.97 (0.94-1.01) .193 0.96 (0.92-1.00) .146

CI, confidence interval.

Model was adjusted for sex, age, body mass index, smoking status, history of hypertension, history of cardiovascular disease, chronic obstructive pulmonary disease, and socioeconomic deprivation.